2012 VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GE... von Detishin, V, Haazen, W, Robison, H, Robarge, L, Olek, E

Volltext

458 FINAL RESULTS OF THE PHARMACOKINETICS, EFFICACY, AND SAFETY/TOLERABILITY OF 400 AND 600 MG ONCE-DAILY DOSING OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) IN HCV GENOTYPE 1 von Detishin, V, Haazen, W, Hooijmaijers, R, Ruppert, M, Bol, K, Robison, H, Robarge, L, Agarwal, A, Deshpande, M, Olek, E

Volltext